{"disease":{"id":"recurrent-glioblastoma-multiforme","name":"recurrent glioblastoma multiforme"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03423628","title":"A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT02974738","title":"A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT06616727","title":"The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM","phase":"PHASE1","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":50,"lead_sponsor_name":"Shanghai Simnova Biotechnology Co.,Ltd.","has_results":false},{"nct_id":"NCT07416188","title":"Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT04689087","title":"A Prospective, Open-label, Single-arm Clinical Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01934361","title":"Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07497373","title":"A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Jecho Biopharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT06613841","title":"Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT03615404","title":"Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Gary Archer Ph.D.","has_results":true},{"nct_id":"NCT04782609","title":"Study of Icapamespib (PU-AD) in Patients With Recurrent Malignant Glioma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Samus Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04915404","title":"Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"WPD Pharmaceuticals Sp. z o.o.","has_results":false},{"nct_id":"NCT06193174","title":"Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT03311542","title":"Expanded Access for Pembrolizumab (MK-3475)","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Center Trials & Treatment","has_results":false}],"total":13},"guidelines":[],"source":"Drug Landscape verified database"}